QA
BEAM icon

Quattro Advisors’s Beam Therapeutics BEAM Stock Holding History

Quattro Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-273
Closed -$7.57K – 105
2025
Q4 		$7.57K Buy
+273
New +$6.96K 0.01% 253

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Quattro Advisors's BEAM Position: Q1 2026 in Review

Quattro Advisors sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 273 shares — an estimated $7.57K sold.

Quattro Advisors first reported a position in BEAM in Q4 2025 and held it in 1 quarter. The position peaked at $7.57K in Q4 2025. 252 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Quattro Advisors reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Quattro Advisors sold 273 Beam Therapeutics shares in Q1 2026, an estimated $7.57K.
  • Quattro Advisors first reported a position in Beam Therapeutics in Q4 2025 and held it in 1 quarter.
  • Quattro Advisors's Beam Therapeutics position peaked at $7.57K in Q4 2025.
  • 252 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Quattro Advisors's 13F filing for Q1 2026, filed 15 May 2026.